Compare DAN & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAN | SUPN |
|---|---|---|
| Founded | 1904 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.0B |
| IPO Year | 1998 | 2010 |
| Metric | DAN | SUPN |
|---|---|---|
| Price | $36.00 | $48.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $40.60 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 844.4K | 443.9K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | ★ 264.10 | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $7,500,000,000.00 | $392,755,000.00 |
| Revenue This Year | $1.89 | $22.70 |
| Revenue Next Year | $4.59 | $19.14 |
| P/E Ratio | $57.38 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.16 | $29.16 |
| 52 Week High | $39.56 | $59.68 |
| Indicator | DAN | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 50.41 | 39.88 |
| Support Level | $34.66 | $47.58 |
| Resistance Level | $36.28 | $52.26 |
| Average True Range (ATR) | 1.34 | 1.56 |
| MACD | -0.26 | -0.21 |
| Stochastic Oscillator | 26.73 | 18.87 |
Dana Inc is engaged in the designing and manufacturing of efficient propulsion and energy-management solutions that power vehicles and machines in all mobility markets across the globe. The company has four operating segments: Light Vehicles, Power Technologies, Commercial Vehicle, and Off-Highway. The Light Vehicles segment generates the majority portion of revenue by providing products to support light vehicle OEMs. Its products are designed for light trucks, SUVs, CUVs, vans, and passenger cars.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.